Chemical compounds that target multiple critical protein kinases or specific ones (i.e., in the case of tumours that are highly dependent on a single genetic aberration) may turn out to be a clinical success, since the success rate for bringing cancer drugs to the market is very limited [6]. The gene discussed is WEE1; the disease is neoplasm.